Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Current and emerging treatments for Waldenström’s macroglobulinemia

Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses available and emerging treatments for Waldenström’s macroglobulinemia (WM). Patients with WM are either treated with fixed-duration chemoimmunotherapy or with continuous BTK inhibitor treatment. Novel therapies including bispecific antibodies, CAR-T therapy, and PROTACs are currently being developed for WM. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


GSK: Honoraria; Takeda: Honoraria; Pfizer: Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.